MetasTx is developing targeted therapies that inhibit prostate cancer metastasis by utilizing IPA-3, a selective inhibitor of Group-1 P21 activated kinases (PAK). This approach aims to improve patient outcomes without the adverse effects associated with traditional androgen deprivation therapies.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for prostate cancer metastasis often lack specificity and can cause significant adverse effects, such as those associated with androgen deprivation therapies. Existing drug discovery efforts in metastatic cancer have not yielded therapies with substantial improvements in patient survival or targeted drug delivery.
Solution
MetasTx is developing targeted therapeutics designed to prevent and treat prostate cancer metastasis without the harmful side effects of traditional androgen deprivation. Their approach centers on selective inhibition of Group-1 P21 activated kinases (PAK), which are pivotal in cancer initiation and metastasis. The company's lead candidate, MTX-101, demonstrates superior stability and efficacy in inhibiting prostate tumor growth and metastasis in preclinical models. MetasTx's therapies aim to improve patient outcomes by modulating metastasis and offering broad applicability across solid tumor cancers.
Target Audience
The primary target audience includes patients with prostate cancer at risk of or already experiencing metastasis, and the physicians who treat them.
Features
- Selective inhibition of Group-1 P21 activated kinases (PAK)
- MTX-101 demonstrates superior stability and efficacy in inhibiting prostate tumor growth and metastasis in preclinical models
- Designed to modulate metastasis without affecting the androgen system